The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index; 18 of the 26 sources its claims cite were checked for support.
Preservation of lean soft tissue during weight loss induced by GLP-1 and GLP-1/GIP receptor agonists: A case series
Open accessAbstract
GLP-1 receptor agonists (e.g., semaglutide) and dual GLP-1/GIP receptor agonists (e.g., tirzepatide) are effective for reducing body weight and fat mass, though lean soft tissue loss comprised 26%–40% of weight loss in recent trials. This case series describes three patients (two female, one male; body mass index: 32.9–51.9 kg m −2 ) who prioritized lean soft tissue preservation strategies during treatment with semaglutide or tirzepatide. Patients engaged in intentional exercise or structured physical activity 4–7 days·week −1 , including resistance training 3–5 days·week −1 . Typical protein intakes were 0.7–1.7 g·kg −1 ·day −1 relative to body mass and 1.6–2.3 g·kg −1 ·day −1 relative to fat-free mass. Changes in weight, fat mass, and lean soft tissue were: −33.0%, −53.4%, and −6.9% (case 1); −26.8%, −61.6%, and +2.5% (case 2); and −13.2%, −46.9%, and +5.8% (case 3). Accordingly, one patient lost 8.7% of weight as lean soft tissue, while two increased lean soft tissue. These findings highlight the potential for some individuals to preserve or even increase lean soft tissue during treatment with semaglutide or tirzepatide alongside supportive lifestyle strategies.
Overview
CoChat Summary
## TL;DR
This case series reports three patients using semaglutide or tirzepatide who lost substantial weight while preserving lean soft tissue, and two of the three increased lean soft tissue over follow-up. The authors suggest that consistent exercise, especially resistance training, plus adequate protein intake may have contributed.
## Key findings
- Across the three cases, weight change, fat mass change, and lean soft tissue (LST) change were: −33.0%, −53.4%, and −6.9% (case 1); −26.8%, −61.6%, and +2.5% (case 2); and −13.2%, −46.9%, and +5.8% (case 3).
- In terms of how much weight loss was attributable to LST, one patient lost 8.7% of weight as LST, while two increased LST.
- The paper notes that in recent GLP-1/GLP-1/GIP trials, about 26%–40% of weight loss was due to lean soft tissue loss by DXA, and a network meta-analysis reported ~25% lean loss.
- In these cases, the patients reported exercising 4–7 days/week, including resistance training 3–5 days/week, with typical protein intakes of 0.7–1.7 g/kg/day by body mass and 1.6–2.3 g/kg/day by fat-free mass.
## Methods
- Design: Case series of three patients treated with semaglutide or tirzepatide and followed with serial DXA body composition measurements.
- Sample/data: Patients came from a virtual health clinic; eligible participants had DXA results across obesity medication treatment plus records of nutrition and exercise habits. The sample included two females and one male, with baseline BMI 32.9–51.9 kg/m².
- Main analysis: Descriptive comparison of DXA-derived body composition variables (body mass, BMI, LST, fat mass, and body fat %) from baseline to final assessment, alongside self-reported nutrition, supplementation, and exercise questionnaires.
## Limitations
- The authors explicitly state this was “simple observation in a very small number of patients without a control group,” so causal inference is limited.
- They state the study relied on self-reports for nutrition and physical activity, so recall bias and social expectation bias are possible.
- They state the findings are not generalizable to all patients.
- Evident from the text: DXA scans were done at different fee-for-service facilities across participants, which may add measurement variability, although each participant was scanned at the same facility over time.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
13 Valid · 0 Not valid · 4 Not checked · 29 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“In the SURMOUNT-1 trial, 124 participants treated with tirzepatide in the DXA subset lost 5.6 kg (~11%) LST in comparison with 15.9 kg (~34%) FM, 9 corresponding to ~26% of weight loss as LST.”
§ Preservation of lean soft tissue during weight loss induced by GLP-1 and GLP-1/GIP receptor agonists: A case series > Introduction Since the U.S. FDA approval of semaglutide (2021) and tirzepatide (2023) for chronic weight management, the use of incretin-based therapies for obesity treatment has accelerated rapidly. A 2024 poll indicated that ~12% of U.S. adults have used incretin-based drugs for weight loss, including ~6% who were currently being treated. 1 The increased use of these therapies reflects their notable efficacy in clinical trials. In the STEP 1 trial, 2.4 mg·week−1 of the glucagon-like peptide-1 receptor agonist (GLP-1RA) semaglutide resulted in 15% mean weight loss over 68 weeks. 2 Subsequently, 5–15 mg·week−1 of tirzepatide—a dual GLP-1 and glucose-dependent insulinotropic polypeptide receptor agonist (GLP-1/GIP RA)—led to mean weight loss of 15%–21% in 72 weeks in the SURMOUNT-1 trial. 3 While this degree of weight loss is meaningful, 4 much recent discussion has centered on the composition of weight loss, particularly the potential for disproportionate loss of various “lean” components, such as fat-free mass (FFM), lean soft tissue (LST), and skeletal muscle mass.5–8 Both STEP 1 and SURMOUNT-1 trials included dual-energy X-ray absorptiometry (DXA) body composition assessments in a subset of participants.2,9 DXA, as a molecular-level assessment, provides estimates of LST (i.e., total mass minus fat mass (FM) and bone mineral mass) or FFM (total mass minus FM); in contrast, organ/tissue-level techniques like magnetic resonance imaging and computed tomography are required to provide direct estimates of skeletal muscle mass.7,10 In the STEP 1 trial, 95 participants treated with semaglutide in the DXA subset lost 6.9 kg (~13%) LST alongside 10.4 kg (~25%) FM, 2 corresponding to ~40% of weight loss as LST. In the SURMOUNT-1 trial, 124 participants treated with tirzepatide in the DXA subset lost 5.6 kg (~11%) LST in comparison with 15.9 kg (~34%) FM, 9 corresponding to ~26% of weight loss as LST. While numerous factors influence the proportion of LST lost, 25% of weight loss as LST or FFM is often used as a general benchmark to evaluate if lean loss is relatively low or high, although this generalization has been critiqued. 11 Among other factors, exercise and targeted nutritional intakes have been proposed to influence body composition outcomes during treatment with incretin-based medications, although these practices have been minimally examined in this context.7,12,13 While controlled trials are needed to evaluate the extent to which targeted lifestyle changes can enhance body composition changes in patients being treated with modern obesity drugs, examining cases of free-living patients may also help inform the potential of such practices and illustrate individual changes that may be observed with lifestyle practices differing from those implemented in clinical trials to date. Accordingly, the purpose of this case series is to present detailed information concerning the DXA body composition changes observed in individuals who have implemented common best practices for maintenance of LST and skeletal muscle mass, such as structured resistance training and an emphasis on dietary protein intake.
What the sources say
- Supportedcites [9] source
The Abstract Results identify 124 tirzepatide-treated participants with baseline and end-of-study DXA data. The Results, “Change in body composition,” report losses of 5.6 kg (10.9%) lean mass and 15.9 kg (33.9%) fat mass, with 26% of weight reduction attributable to lean mass. The Methods, “Procedures,” equate DXA lean mass with lean soft tissue. (LLM, conf=0.95)
plainstates a causen = 124- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In the STEP 1 trial, 95 participants treated with semaglutide in the DXA subset lost 6.9 kg (~13%) LST alongside 10.4 kg (~25%) FM, 2 corresponding to ~40% of weight loss as LST.”
§ Preservation of lean soft tissue during weight loss induced by GLP-1 and GLP-1/GIP receptor agonists: A case series > Introduction Since the U.S. FDA approval of semaglutide (2021) and tirzepatide (2023) for chronic weight management, the use of incretin-based therapies for obesity treatment has accelerated rapidly. A 2024 poll indicated that ~12% of U.S. adults have used incretin-based drugs for weight loss, including ~6% who were currently being treated. 1 The increased use of these therapies reflects their notable efficacy in clinical trials. In the STEP 1 trial, 2.4 mg·week−1 of the glucagon-like peptide-1 receptor agonist (GLP-1RA) semaglutide resulted in 15% mean weight loss over 68 weeks. 2 Subsequently, 5–15 mg·week−1 of tirzepatide—a dual GLP-1 and glucose-dependent insulinotropic polypeptide receptor agonist (GLP-1/GIP RA)—led to mean weight loss of 15%–21% in 72 weeks in the SURMOUNT-1 trial. 3 While this degree of weight loss is meaningful, 4 much recent discussion has centered on the composition of weight loss, particularly the potential for disproportionate loss of various “lean” components, such as fat-free mass (FFM), lean soft tissue (LST), and skeletal muscle mass.5–8 Both STEP 1 and SURMOUNT-1 trials included dual-energy X-ray absorptiometry (DXA) body composition assessments in a subset of participants.2,9 DXA, as a molecular-level assessment, provides estimates of LST (i.e., total mass minus fat mass (FM) and bone mineral mass) or FFM (total mass minus FM); in contrast, organ/tissue-level techniques like magnetic resonance imaging and computed tomography are required to provide direct estimates of skeletal muscle mass.7,10 In the STEP 1 trial, 95 participants treated with semaglutide in the DXA subset lost 6.9 kg (~13%) LST alongside 10.4 kg (~25%) FM, 2 corresponding to ~40% of weight loss as LST. In the SURMOUNT-1 trial, 124 participants treated with tirzepatide in the DXA subset lost 5.6 kg (~11%) LST in comparison with 15.9 kg (~34%) FM, 9 corresponding to ~26% of weight loss as LST. While numerous factors influence the proportion of LST lost, 25% of weight loss as LST or FFM is often used as a general benchmark to evaluate if lean loss is relatively low or high, although this generalization has been critiqued. 11 Among other factors, exercise and targeted nutritional intakes have been proposed to influence body composition outcomes during treatment with incretin-based medications, although these practices have been minimally examined in this context.7,12,13 While controlled trials are needed to evaluate the extent to which targeted lifestyle changes can enhance body composition changes in patients being treated with modern obesity drugs, examining cases of free-living patients may also help inform the potential of such practices and illustrate individual changes that may be observed with lifestyle practices differing from those implemented in clinical trials to date. Accordingly, the purpose of this case series is to present detailed information concerning the DXA body composition changes observed in individuals who have implemented common best practices for maintenance of LST and skeletal muscle mass, such as structured resistance training and an emphasis on dietary protein intake.
What the sources say
- Partly supportedcites [2] sourceExperimental — accuracy not yet measured
The Change in Body Composition section reports that fat mass and lean body mass decreased with semaglutide in the DXA subpopulation, and the Discussion says the reduction in fat mass was greater. Our copy does not give the claimed 95-person treatment-group count, the 6.9 kg and 10.4 kg losses, their percentages, or the estimate that lean soft tissue made up about 40% of weight loss. (LLM, conf=0.84)
plainstates a causen = 95- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“though lean soft tissue loss comprised 26%–40% of weight loss in recent trials”
- Also stated in: § Discussion · hedged
“approximately 26%–40% of weight loss is due to loss of LST when evaluated by DXA.2,9”
§ Preservation of lean soft tissue during weight loss induced by GLP-1 and GLP-1/GIP receptor agonists: A case series > Abstract
What the sources say
- Partly supportedcites [2] sourceExperimental — accuracy not yet measured
The Change in Body Composition section reports that lean body mass decreased in the semaglutide DXA subpopulation, supporting lean-mass loss during treatment. Our copy does not give the claimed 26%–40% share of weight loss or report a trial of a dual GLP-1/GIP receptor agonist. (LLM, conf=0.85)
- Supportedcites [9] source
The Introduction defines the paper’s measure of lean mass as lean soft tissue mass. The Results report that lean mass accounted for 26% of weight lost with tirzepatide, and the Discussion reports 40% in the semaglutide STEP 1 trial. Together, those passages support the stated range across the two treatments. (LLM, conf=0.92)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Discussion · hedged
Every source the paper cites for this claim was checked and supports it.
In the paper
“In the STEP 1 trial, 2.4 mg·week−1 of the glucagon-like peptide-1 receptor agonist (GLP-1RA) semaglutide resulted in 15% mean weight loss over 68 weeks. 2”
§ Preservation of lean soft tissue during weight loss induced by GLP-1 and GLP-1/GIP receptor agonists: A case series > Introduction Since the U.S. FDA approval of semaglutide (2021) and tirzepatide (2023) for chronic weight management, the use of incretin-based therapies for obesity treatment has accelerated rapidly. A 2024 poll indicated that ~12% of U.S. adults have used incretin-based drugs for weight loss, including ~6% who were currently being treated. 1 The increased use of these therapies reflects their notable efficacy in clinical trials. In the STEP 1 trial, 2.4 mg·week−1 of the glucagon-like peptide-1 receptor agonist (GLP-1RA) semaglutide resulted in 15% mean weight loss over 68 weeks. 2 Subsequently, 5–15 mg·week−1 of tirzepatide—a dual GLP-1 and glucose-dependent insulinotropic polypeptide receptor agonist (GLP-1/GIP RA)—led to mean weight loss of 15%–21% in 72 weeks in the SURMOUNT-1 trial. 3 While this degree of weight loss is meaningful, 4 much recent discussion has centered on the composition of weight loss, particularly the potential for disproportionate loss of various “lean” components, such as fat-free mass (FFM), lean soft tissue (LST), and skeletal muscle mass.5–8 Both STEP 1 and SURMOUNT-1 trials included dual-energy X-ray absorptiometry (DXA) body composition assessments in a subset of participants.2,9 DXA, as a molecular-level assessment, provides estimates of LST (i.e., total mass minus fat mass (FM) and bone mineral mass) or FFM (total mass minus FM); in contrast, organ/tissue-level techniques like magnetic resonance imaging and computed tomography are required to provide direct estimates of skeletal muscle mass.7,10 In the STEP 1 trial, 95 participants treated with semaglutide in the DXA subset lost 6.9 kg (~13%) LST alongside 10.4 kg (~25%) FM, 2 corresponding to ~40% of weight loss as LST. In the SURMOUNT-1 trial, 124 participants treated with tirzepatide in the DXA subset lost 5.6 kg (~11%) LST in comparison with 15.9 kg (~34%) FM, 9 corresponding to ~26% of weight loss as LST. While numerous factors influence the proportion of LST lost, 25% of weight loss as LST or FFM is often used as a general benchmark to evaluate if lean loss is relatively low or high, although this generalization has been critiqued. 11 Among other factors, exercise and targeted nutritional intakes have been proposed to influence body composition outcomes during treatment with incretin-based medications, although these practices have been minimally examined in this context.7,12,13 While controlled trials are needed to evaluate the extent to which targeted lifestyle changes can enhance body composition changes in patients being treated with modern obesity drugs, examining cases of free-living patients may also help inform the potential of such practices and illustrate individual changes that may be observed with lifestyle practices differing from those implemented in clinical trials to date. Accordingly, the purpose of this case series is to present detailed information concerning the DXA body composition changes observed in individuals who have implemented common best practices for maintenance of LST and skeletal muscle mass, such as structured resistance training and an emphasis on dietary protein intake.
What the sources say
- Supportedcites [2] source
The Discussion reports 14.9% mean weight loss from baseline in the semaglutide group, which rounds to 15%. The Procedures specify a 68-week trial with a 2.4 mg once-weekly maintenance dose; treatment also included lifestyle intervention. (LLM, conf=0.95)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“However, a study directly comparing different modalities of exercise found that exercise programs including resistance training may be particularly effective at reducing the loss of thigh skeletal muscle volume during weight loss. 19”
§ Preservation of lean soft tissue during weight loss induced by GLP-1 and GLP-1/GIP receptor agonists: A case series > Discussion
What the sources say
- Supportedcites [19] source
The Methods (Baseline Assessments; page not provided) state that thigh muscle volume was measured by MRI. The Results (Body Composition; page not provided) report that thigh muscle changes followed the same pattern as lean mass, which declined less with resistance or combined training than with aerobic training during weight loss in obese older adults. (LLM, conf=0.92)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
18 more claims
Create a free account to see all 46 claims and every source verdict.
- Probably not a substantial claim. 17
- It may state two separate claims as one. 16
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Evidence suggests that combining resistance exercise with GLP-1 RAs not only helps preserve lean mass but also leads to improvements in physical performance metrics, such as mobility, balance and strength [65].”
From A Narrative Review on GLP-1 Receptor Agonists for Obesity in Older Women: Maximizing Weight Loss While Preserving Lean Mass (2026) · cites this paper as [65]
Experimental — accuracy not yet measured
Citations
Cites
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Tirzepatide Once Weekly for the Treatment of Obesity
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206038 · Cited by 3,838
Garvey, W. T., Mechanick, J. I., Brett, E. M., Garber, A. J., Hurley, D. L., Jastreboff, A. M., Nadolsky, K., Pessah-Pollack, R., & Plodkowski, R. (2016) · Endocrine Practice · doi:10.4158/ep161365.gl · Cited by 1,914
Aerobic or Resistance Exercise, or Both, in Dieting Obese Older Adults
Villareal, D. T., Aguirre, L., Gurney, A. B., Waters, D. L., Sinacore, D. R., Colombo, E., Armamento-Villareal, R., & Qualls, C. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1616338 · Cited by 754
Wycherley, T. P., Moran, L. J., Clifton, P. M., Noakes, M., & Brinkworth, G. D. (2012) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.112.044321 · Cited by 606
Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined
Lundgren, J. R., Janus, C., Jensen, S. B. K., Juhl, C. R., Olsen, L. M., Christensen, R. M., Svane, M. S., Bandholm, T., Bojsen-Møller, K. N., Blond, M. B., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2028198 · Cited by 536 · cited 1×
“In that regard, Lundgren et al. 20 demonstrated that the addition of an exercise program to lira-glutide treatment preserved FFM and potentiated FM loss following an initial low-calorie diet period, eliciting weight loss.”
The role of protein in weight loss and maintenance
Leidy, H. J., Clifton, P. M., Astrup, A., Wycherley, T. P., Westerterp-Plantenga, M. S., Luscombe-Marsh, N. D., Woods, S. C., & Mattes, R. D. (2015) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.114.084038 · Cited by 475 · cited 1×
“27 However, there are limitations to considering protein intakes relative to BM in the context of obesity and substantial weight loss, and expressing intakes relative to FFM may be preferable in this context.”
Protein "requirements" beyond the RDA: implications for optimizing health
Phillips, S. M., Chevalier, S., & Leidy, H. J. (2016) · Applied Physiology, Nutrition, and Metabolism · doi:10.1139/apnm-2015-0550 · Cited by 396
Changes in lean body mass with glucagon‐like peptide ‐1‐based therapies and mitigation strategies
Neeland, I. J., Linge, J., & Birkenfeld, A. L. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15728 · Cited by 391
Weinheimer, E. M., Sands, L. P., & Campbell, W. W. (2010) · Nutrition Reviews · doi:10.1111/j.1753-4887.2010.00298.x · Cited by 391
Cited by
Moscucci, F., Baratta, F., Pastori, D., Menichelli, D., Mattioli, A. V., Gallina, S., Lospinuso, I., Sciomer, S., Piccirillo, G., & Desideri, G. (2026) · Nutrients · doi:10.3390/nu18040632 · Cited by 11
“Evidence suggests that combining resistance exercise with GLP-1 RAs not only helps preserve lean mass but also leads to improvements in physical performance metrics, such as mobility, balance and strength [65].”
Multimodal Prehabilitation for Hernia Repair: Linking Metabolic Modulation and Mechanical Methods
Păduraru, D. N., Palcău, A. C., Daniel, I., & Seicaru, R. (2025) · Biomedicines · doi:10.3390/biomedicines13123117 · Cited by 8
“Critically, the weight loss induced by these agents predominantly reflects reductions in visceral and subcutaneous adipose tissue, with relative preservation of lean body mass [72], even though the results described in the literature are controversial [73].”
Al-Awadi, A. A., Alroudhan, D., Alsaeed, D., Almarshad, B. W., Alshehabi, D. H., Al‐Lahou, B., Mashankar, A., Al‐Ozairi, E., & Gray, S. (2026) · BMJ Open · doi:10.1136/bmjopen-2026-116911 · Cited by 16
“Tinsley and Nadolsky 34 report a small, uncontrolled case series with limited generalisability, while Barana et al (2025) 35 emphasise the potential role of nutrition and exercise but highlight the lack of rigorous interventional trials.”
Zambrano-Villacres, R., Campuzano-Donoso, M., Reytor-González, C., Rossetti, G., Cobellis, L., Cobellis, F., Pilone, V., Simancas‐Racines, D., & Schiavo, L. (2026) · Nutrients · doi:10.3390/nu18111751 · Cited by 8
“Clinical studies demonstrate that GLP-1-based treatments significantly reduce spontaneous energy intake, which can inadvertently lower protein consumption below levels required to preserve lean body mass during weight loss [91].”
Schmidt, P. H. S., de Souza, V. S. N., Machado, L. G., Rodrigues, J. V. A., da Cruz, J. V. R., de Souza, L. S. N., dos Santos, B. E., Hohl, A., Ronsoni, M. F., & van de Sande‐Lee, S. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70529 · Cited by 7
“11 Despite these benefits, concerns have arisen regarding the impact of pharmacologically induced weight loss on body composition, particularly the potential loss of lean mass, which may impair metabolic health and physical functioning.”
Metadata
- Authors
- Tinsley, G. M., & Nadolsky, S.
- Affiliations
- Texas Tech University (US)
- Vineyard Health, Holland, MI, USA
- Corresponding author
- Tinsley, Grant M.
- ORCID
- Tinsley, Grant M.
- Venue
- SAGE Open Medical Case Reports
- Publisher
- SAGE Publications
- Published
- 2025-10
- Volume
- 13
- Pages
- 2050313X251388724-2050313X251388724
- ISSN
- 2050-313X (ISSN-L)
- PMC
- PMC12536186
- OpenAlex
- W4415260741
- Cited by
- 15
- References
- 27
- Citations by year
- 2026: 14 · 2025: 1
- FWCI
- 10.23
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc
- creativecommons.org/licenses/by-nc/4.0/ (vor)
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- SAGE Open Medical Case Reports (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- OSF Preprints (OSF Preprints) (submittedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Physiology (medical) › Nutrition and Health in Aging
- Keywords
- GLP-1 receptor agonists, semaglutide, tirzepatide, GIP/GLP-1 receptor agonist, weight loss, fat loss, resistance training, protein intake, fat-free mass, obesity, lifestyle intervention
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Preservation of lean soft tissue during weight loss induced by GLP-1 and GLP-1/GIP receptor agonists: A case series. https://app.cochat.ai/papers/10.1177/2050313x251388724
- The paper
- Tinsley, G. M., & Nadolsky, S. (2025). Preservation of lean soft tissue during weight loss induced by GLP-1 and GLP-1/GIP receptor agonists: A case series. SAGE Open Medical Case Reports. https://doi.org/10.1177/2050313x251388724
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.